Ventolin Rotacaps

Hyperkalemia, Acute Bronchitis, Pneumonia + 18 more
Treatment
9 FDA approvals
20 Active Studies for Ventolin Rotacaps

What is Ventolin Rotacaps

SalbutamolThe Generic name of this drug
Treatment SummarySalbutamol is a medication used to treat asthma and COPD. It works by activating beta2-receptors in the lungs to reduce symptoms such as wheezing, coughing, and difficulty breathing. Salbutamol is a mix of two different forms (R- and S-isomers), with the R-isomer being more effective. A more expensive, single R-isomer version of the drug (Levalbuterol) is also available, but salbutamol is more commonly prescribed. Salbutamol is used to treat both acute episodes of bronchospasm and to prevent exercise-
Proair HFAis the brand name
image of different drug pills on a surface
Ventolin Rotacaps Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Proair HFA
Salbutamol
1981
314

Approved as Treatment by the FDA

Salbutamol, also known as Proair HFA, is approved by the FDA for 9 uses like prophylaxis of Exercise-induced bronchospasm and Bronchospasm, Exercise-Induced .
prophylaxis of Exercise-induced bronchospasm
Bronchospasm, Exercise-Induced
Bronchial Spasm
Asthma, Exercise-Induced
Chronic Obstructive Pulmonary Disease
Used to treat Chronic Obstructive Pulmonary Disease (COPD) in combination with Ipratropium
Bronchodilator Agents
Used to treat need of more than one bronchodilator in combination with Ipratropium
prophylaxis of Bronchospasm
Exercise-Induced Bronchospasm
Bronchospasm

Effectiveness

How Ventolin Rotacaps Affects PatientsSalbutamol (also known as albuterol) is a medication used to open up airways and relieve breathing problems like asthma. It works by stimulating beta-1 and beta-2 receptors in the body, which helps to relax the muscles in the lungs. Side effects can include trembling muscles, lower blood pressure, and changes in insulin and blood sugar levels. It can also lower potassium levels in the blood. Salbutamol is similar to another medication called terbutaline, but the version of salbutamol called levalbuterol is thought to have fewer side effects.
How Ventolin Rotacaps works in the bodySalbutamol works by relaxing the muscles in the airways, which allows more air to flow through. It does this by activating beta2-adrenergic receptors on the airway muscles, which triggers a series of chemical reactions that result in muscle relaxation. Salbutamol is especially useful because it is more effective on the airways than similar drugs and has fewer side effects on the heart. After inhalation, it usually takes 5-15 minutes for airway relaxation to begin, and the effects can last for up to 6 hours.

When to interrupt dosage

The suggested quantity of Ventolin Rotacaps is founded on the diagnosed condition, including Bronchodilator Agents, Emphysema and Wheezing. The amount of dosage changes, in line with the technique of administration featured in the table beneath.
Condition
Dosage
Administration
Hyperkalemia
2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation
, Oral, Syrup, Syrup - Oral, Respiratory (inhalation), Solution, Solution - Respiratory (inhalation), Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet - Oral, Tablet, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Intramuscular, Liquid - Intramuscular, Capsule, Capsule - Respiratory (inhalation), Liquid - Oral, Solution - Intramuscular, Spray, metered - Respiratory (inhalation), Spray, metered, Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant, Inhalant - Respiratory (inhalation), Aerosol, spray, Aerosol, spray - Oral, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Nasal, Inhalant - Oral, Solution - Nasal
Acute Bronchitis
2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation
, Oral, Syrup, Syrup - Oral, Respiratory (inhalation), Solution, Solution - Respiratory (inhalation), Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet - Oral, Tablet, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Intramuscular, Liquid - Intramuscular, Capsule, Capsule - Respiratory (inhalation), Liquid - Oral, Solution - Intramuscular, Spray, metered - Respiratory (inhalation), Spray, metered, Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant, Inhalant - Respiratory (inhalation), Aerosol, spray, Aerosol, spray - Oral, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Nasal, Inhalant - Oral, Solution - Nasal
Pneumonia
2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation
, Oral, Syrup, Syrup - Oral, Respiratory (inhalation), Solution, Solution - Respiratory (inhalation), Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet - Oral, Tablet, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Intramuscular, Liquid - Intramuscular, Capsule, Capsule - Respiratory (inhalation), Liquid - Oral, Solution - Intramuscular, Spray, metered - Respiratory (inhalation), Spray, metered, Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant, Inhalant - Respiratory (inhalation), Aerosol, spray, Aerosol, spray - Oral, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Nasal, Inhalant - Oral, Solution - Nasal
Bronchial Spasm
2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation
, Oral, Syrup, Syrup - Oral, Respiratory (inhalation), Solution, Solution - Respiratory (inhalation), Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet - Oral, Tablet, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Intramuscular, Liquid - Intramuscular, Capsule, Capsule - Respiratory (inhalation), Liquid - Oral, Solution - Intramuscular, Spray, metered - Respiratory (inhalation), Spray, metered, Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant, Inhalant - Respiratory (inhalation), Aerosol, spray, Aerosol, spray - Oral, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Nasal, Inhalant - Oral, Solution - Nasal
Asthma
2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation
, Oral, Syrup, Syrup - Oral, Respiratory (inhalation), Solution, Solution - Respiratory (inhalation), Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet - Oral, Tablet, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Intramuscular, Liquid - Intramuscular, Capsule, Capsule - Respiratory (inhalation), Liquid - Oral, Solution - Intramuscular, Spray, metered - Respiratory (inhalation), Spray, metered, Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant, Inhalant - Respiratory (inhalation), Aerosol, spray, Aerosol, spray - Oral, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Nasal, Inhalant - Oral, Solution - Nasal
prophylaxis of Bronchospasm
2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation
, Oral, Syrup, Syrup - Oral, Respiratory (inhalation), Solution, Solution - Respiratory (inhalation), Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet - Oral, Tablet, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Intramuscular, Liquid - Intramuscular, Capsule, Capsule - Respiratory (inhalation), Liquid - Oral, Solution - Intramuscular, Spray, metered - Respiratory (inhalation), Spray, metered, Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant, Inhalant - Respiratory (inhalation), Aerosol, spray, Aerosol, spray - Oral, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Nasal, Inhalant - Oral, Solution - Nasal
Asthma
2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation
, Oral, Syrup, Syrup - Oral, Respiratory (inhalation), Solution, Solution - Respiratory (inhalation), Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet - Oral, Tablet, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Intramuscular, Liquid - Intramuscular, Capsule, Capsule - Respiratory (inhalation), Liquid - Oral, Solution - Intramuscular, Spray, metered - Respiratory (inhalation), Spray, metered, Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant, Inhalant - Respiratory (inhalation), Aerosol, spray, Aerosol, spray - Oral, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Nasal, Inhalant - Oral, Solution - Nasal
Respiratory Tract Infections
2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation
, Oral, Syrup, Syrup - Oral, Respiratory (inhalation), Solution, Solution - Respiratory (inhalation), Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet - Oral, Tablet, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Intramuscular, Liquid - Intramuscular, Capsule, Capsule - Respiratory (inhalation), Liquid - Oral, Solution - Intramuscular, Spray, metered - Respiratory (inhalation), Spray, metered, Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant, Inhalant - Respiratory (inhalation), Aerosol, spray, Aerosol, spray - Oral, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Nasal, Inhalant - Oral, Solution - Nasal
Bronchitis, Chronic
2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation
, Oral, Syrup, Syrup - Oral, Respiratory (inhalation), Solution, Solution - Respiratory (inhalation), Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet - Oral, Tablet, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Intramuscular, Liquid - Intramuscular, Capsule, Capsule - Respiratory (inhalation), Liquid - Oral, Solution - Intramuscular, Spray, metered - Respiratory (inhalation), Spray, metered, Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant, Inhalant - Respiratory (inhalation), Aerosol, spray, Aerosol, spray - Oral, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Nasal, Inhalant - Oral, Solution - Nasal
Asthma, Exercise-Induced
2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation
, Oral, Syrup, Syrup - Oral, Respiratory (inhalation), Solution, Solution - Respiratory (inhalation), Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet - Oral, Tablet, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Intramuscular, Liquid - Intramuscular, Capsule, Capsule - Respiratory (inhalation), Liquid - Oral, Solution - Intramuscular, Spray, metered - Respiratory (inhalation), Spray, metered, Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant, Inhalant - Respiratory (inhalation), Aerosol, spray, Aerosol, spray - Oral, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Nasal, Inhalant - Oral, Solution - Nasal
Airway secretion clearance therapy
2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation
, Oral, Syrup, Syrup - Oral, Respiratory (inhalation), Solution, Solution - Respiratory (inhalation), Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet - Oral, Tablet, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Intramuscular, Liquid - Intramuscular, Capsule, Capsule - Respiratory (inhalation), Liquid - Oral, Solution - Intramuscular, Spray, metered - Respiratory (inhalation), Spray, metered, Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant, Inhalant - Respiratory (inhalation), Aerosol, spray, Aerosol, spray - Oral, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Nasal, Inhalant - Oral, Solution - Nasal
Asthma
2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation
, Oral, Syrup, Syrup - Oral, Respiratory (inhalation), Solution, Solution - Respiratory (inhalation), Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet - Oral, Tablet, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Intramuscular, Liquid - Intramuscular, Capsule, Capsule - Respiratory (inhalation), Liquid - Oral, Solution - Intramuscular, Spray, metered - Respiratory (inhalation), Spray, metered, Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant, Inhalant - Respiratory (inhalation), Aerosol, spray, Aerosol, spray - Oral, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Nasal, Inhalant - Oral, Solution - Nasal
Bronchodilation
2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation
, Oral, Syrup, Syrup - Oral, Respiratory (inhalation), Solution, Solution - Respiratory (inhalation), Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet - Oral, Tablet, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Intramuscular, Liquid - Intramuscular, Capsule, Capsule - Respiratory (inhalation), Liquid - Oral, Solution - Intramuscular, Spray, metered - Respiratory (inhalation), Spray, metered, Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant, Inhalant - Respiratory (inhalation), Aerosol, spray, Aerosol, spray - Oral, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Nasal, Inhalant - Oral, Solution - Nasal
excess mucus or phlegm
2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation
, Oral, Syrup, Syrup - Oral, Respiratory (inhalation), Solution, Solution - Respiratory (inhalation), Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet - Oral, Tablet, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Intramuscular, Liquid - Intramuscular, Capsule, Capsule - Respiratory (inhalation), Liquid - Oral, Solution - Intramuscular, Spray, metered - Respiratory (inhalation), Spray, metered, Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant, Inhalant - Respiratory (inhalation), Aerosol, spray, Aerosol, spray - Oral, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Nasal, Inhalant - Oral, Solution - Nasal
Bronchodilator Agents
2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation
, Oral, Syrup, Syrup - Oral, Respiratory (inhalation), Solution, Solution - Respiratory (inhalation), Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet - Oral, Tablet, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Intramuscular, Liquid - Intramuscular, Capsule, Capsule - Respiratory (inhalation), Liquid - Oral, Solution - Intramuscular, Spray, metered - Respiratory (inhalation), Spray, metered, Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant, Inhalant - Respiratory (inhalation), Aerosol, spray, Aerosol, spray - Oral, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Nasal, Inhalant - Oral, Solution - Nasal
Bronchospasm, Exercise-Induced
2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation
, Oral, Syrup, Syrup - Oral, Respiratory (inhalation), Solution, Solution - Respiratory (inhalation), Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet - Oral, Tablet, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Intramuscular, Liquid - Intramuscular, Capsule, Capsule - Respiratory (inhalation), Liquid - Oral, Solution - Intramuscular, Spray, metered - Respiratory (inhalation), Spray, metered, Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant, Inhalant - Respiratory (inhalation), Aerosol, spray, Aerosol, spray - Oral, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Nasal, Inhalant - Oral, Solution - Nasal
Emphysema
2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation
, Oral, Syrup, Syrup - Oral, Respiratory (inhalation), Solution, Solution - Respiratory (inhalation), Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet - Oral, Tablet, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Intramuscular, Liquid - Intramuscular, Capsule, Capsule - Respiratory (inhalation), Liquid - Oral, Solution - Intramuscular, Spray, metered - Respiratory (inhalation), Spray, metered, Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant, Inhalant - Respiratory (inhalation), Aerosol, spray, Aerosol, spray - Oral, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Nasal, Inhalant - Oral, Solution - Nasal
Influenza
2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation
, Oral, Syrup, Syrup - Oral, Respiratory (inhalation), Solution, Solution - Respiratory (inhalation), Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet - Oral, Tablet, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Intramuscular, Liquid - Intramuscular, Capsule, Capsule - Respiratory (inhalation), Liquid - Oral, Solution - Intramuscular, Spray, metered - Respiratory (inhalation), Spray, metered, Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant, Inhalant - Respiratory (inhalation), Aerosol, spray, Aerosol, spray - Oral, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Nasal, Inhalant - Oral, Solution - Nasal
Chronic Obstructive Pulmonary Disease
2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation
, Oral, Syrup, Syrup - Oral, Respiratory (inhalation), Solution, Solution - Respiratory (inhalation), Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet - Oral, Tablet, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Intramuscular, Liquid - Intramuscular, Capsule, Capsule - Respiratory (inhalation), Liquid - Oral, Solution - Intramuscular, Spray, metered - Respiratory (inhalation), Spray, metered, Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant, Inhalant - Respiratory (inhalation), Aerosol, spray, Aerosol, spray - Oral, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Nasal, Inhalant - Oral, Solution - Nasal
Bronchitis
2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation
, Oral, Syrup, Syrup - Oral, Respiratory (inhalation), Solution, Solution - Respiratory (inhalation), Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet - Oral, Tablet, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Solution - Intravenous, Intravenous, Powder, Powder - Respiratory (inhalation), Liquid, Liquid - Respiratory (inhalation), Liquid - Intravenous, Intramuscular, Liquid - Intramuscular, Capsule, Capsule - Respiratory (inhalation), Liquid - Oral, Solution - Intramuscular, Spray, metered - Respiratory (inhalation), Spray, metered, Powder, metered, Powder, metered - Respiratory (inhalation), Inhalant, Inhalant - Respiratory (inhalation), Aerosol, spray, Aerosol, spray - Oral, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Nasal, Inhalant - Nasal, Inhalant - Oral, Solution - Nasal

Warnings

There are 20 known major drug interactions with Ventolin Rotacaps.
Common Ventolin Rotacaps Drug Interactions
Drug Name
Risk Level
Description
Hydroxyzine
Major
The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Hydroxyzine.
Mobocertinib
Major
The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Mobocertinib.
Ziprasidone
Major
The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Ziprasidone.
1-benzylimidazole
Minor
The risk or severity of hypertension can be increased when Salbutamol is combined with 1-benzylimidazole.
2,5-Dimethoxy-4-ethylamphetamine
Minor
The risk or severity of hypertension can be increased when Salbutamol is combined with 2,5-Dimethoxy-4-ethylamphetamine.
Ventolin Rotacaps Toxicity & Overdose RiskTaking too much Albuterol can lead to symptoms such as seizures, chest pain, high or low blood pressure, very fast heartbeat, nervousness, headaches, tremors, muscle cramps, dry mouth, palpitations, nausea, dizziness, fatigue, restlessness, difficulty sleeping, high blood sugar, low potassium, and acidosis. There have also been reports of birth defects in animals exposed to Albuterol during pregnancy. Nursing mothers should talk to their doctor before using Albuterol. It is not recommended for young children under the age of 4 due to lack of research. Elderly patients should start
image of a doctor in a lab doing drug, clinical research

Ventolin Rotacaps Novel Uses: Which Conditions Have a Clinical Trial Featuring Ventolin Rotacaps?

383 active clinical trials are currently in progress to assess the potential of Ventolin Rotacaps in alleviating Respiratory Tract Infections, Asthma and Chronic Obstructive Pulmonary Disease (COPD).
Condition
Clinical Trials
Trial Phases
Chronic Obstructive Pulmonary Disease
77 Actively Recruiting
Phase 3, Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 4
Bronchospasm, Exercise-Induced
0 Actively Recruiting
Asthma
92 Actively Recruiting
Phase 1, Phase 4, Early Phase 1, Phase 2, Not Applicable, Phase 3
prophylaxis of Bronchospasm
0 Actively Recruiting
Influenza
29 Actively Recruiting
Not Applicable, Phase 4, Phase 2, Phase 1, Phase 3
Hyperkalemia
4 Actively Recruiting
Phase 3, Not Applicable, Phase 2, Phase 1
Bronchitis, Chronic
0 Actively Recruiting
excess mucus or phlegm
0 Actively Recruiting
Bronchodilator Agents
0 Actively Recruiting
Pneumonia
16 Actively Recruiting
Not Applicable, Early Phase 1, Phase 2
Bronchial Spasm
0 Actively Recruiting
Asthma
1 Actively Recruiting
Phase 2
Airway secretion clearance therapy
0 Actively Recruiting
Respiratory Sounds
5 Actively Recruiting
Phase 2, Phase 3
Asthma
1 Actively Recruiting
Phase 4
Asthma, Exercise-Induced
0 Actively Recruiting
Emphysema
4 Actively Recruiting
Phase 2, Not Applicable
Bronchitis
0 Actively Recruiting
Acute Bronchitis
7 Actively Recruiting
Phase 4, Not Applicable, Phase 3, Early Phase 1
Bronchodilation
0 Actively Recruiting

Ventolin Rotacaps Reviews: What are patients saying about Ventolin Rotacaps?

5Patient Review
6/7/2009
Ventolin Rotacaps for Asthma
This treatment is really easy to use, which I appreciate.
5Patient Review
9/16/2008
Ventolin Rotacaps for Bronchitis
I thought the rotacaps inhaler was easy to use and much better for you than other propellant-based inhalers.
5Patient Review
10/26/2011
Ventolin Rotacaps for Asthma
This treatments is very easy to use, which I appreciate.

Patient Q&A Section about ventolin rotacaps

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How do you take Ventolin Rotacap?

"Adults: 200-400 micrograms of Rotacaps inhaled 3 or 4 times daily via Rotahaler. The maximum dose in 24 hours is 12 Rotacaps. Children (to 12 years): 200 micrograms of Rotacaps inhaled 3 or 4 times daily via Rotahaler. The maximum dose in 24 hours is 6 Rotacaps."

Answered by AI

Is Rotacaps a steroid?

"Foracort 200 Rotacap is a combination of two medicines: Formoterol and Budesonide. Formoterol is a long-acting bronchodilator which works by relaxing the muscles in the airways and widens the airways. Budesonide is a steroid."

Answered by AI

Is Ventolin tablet a steroid?

"Ventolin does not contain steroids. The active ingredient, albuterol, is a bronchodilator that relaxes the smooth muscle in the airways, allowing air to flow in and out of the lungs more easily."

Answered by AI

What is the side effects of Rotacaps inhaler?

"headache, nausea, feeling shaky or tense, heart beating faster than usual, feeling 'warm', mouth or throat irritation"

Answered by AI

Clinical Trials for Ventolin Rotacaps

Image of Stanford University in Stanford, United States.

MoblO2 for Chronic Lung Diseases

18+
All Sexes
Stanford, CA
Many patients with chronic lung disease (e.g., chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD)) require supplemental oxygen (O2) at some point during their disease course. Practitioners prescribe O2 to patients with chronic lung disease in hopes of the following: 1) that it will limit desaturation events and combat breathlessness, thus preventing the frustratingly slow pace and numerous rest breaks patients are forced to adopt while doing even simple tasks; 2) that it will allow patients to be more active physically (perhaps increase their ability to exercise) and socially (perhaps leave the home more often); 3) that it will stave off putative complications of hypoxemia (e.g., cognitive dysfunction, pulmonary hypertension) and 4) that it will improve health-related quality of life (HRQL). However, despite the rationale for O2, and prescribers' good intentions, patients generally view O2 with frustration and fear - it threatens their HRQL, which is already impaired by having a condition that imposes itself on every aspect of their lives. Nasal cannulas and delivery devices call unwanted attention to patients when they are out in public. O2 users feel stigmatized and are often viewed as "smokers who get what they deserve, even if they never smoked a day in their lives" - or as disabled, sick or even infectious. O2 steals patients' independence, forcing them to plan their lives around it. The anxiety that patients and their caregivers experience around running out of oxygen, or not getting enough, immobilizes them and restricts participation in activities outside of the home. O2 disrupts the home environment, adding stress, and creating a burden for patients' caregiver-loved-ones who are often saddled with the responsibility of ensuring adequate equipment and supply of O2, and O2 is a constant reminder to patients they are living with a condition that could shorten their lives. O2 delivery equipment is typically heavy, unwieldy and intimidating. Different recommendations (e.g., insurance companies use 88% as a cut-off for SpO2, while many practitioners focus on 90%) make it confusing for patients, which almost certainly affects adherence. O2-requiringpatients are starving for things that can make their lives easier. An auto-adjusting O2 delivery device - one that automatically delivers the correct amount of O2 to maintain blood oxygen at desired, pre-set levels - would alleviate the need for patients to constantly (incessantly for many) monitor their peripheral oxygen saturation (SpO2) and adjust O2flow to meet the demands as exertion levels vary . The MoblO2 device is a battery-operated, light-weight, closed-loop O2 delivery device that houses a regulator (which attaches to compressed gas O2 tanks) and adjusts O2 flow to meet a pre-set blood oxygen level. A pulse oximeter is worn on the ear and transmits via Bluetooth to the device, which adjusts an internal valve to control flow on a second-to-second basis. The user sets the dial to the highest flow of O2 needed to meet the demands of activities they might perform (up to 15 liters per minute), and the device adjusts flow, up to the pre-set level to maintain SpO2 at a preset level (e.g., \> 90%). To conserve O2 supply in the tank - and to avoid over-oxygenation (which could be problematic for a small percentage of patients with the most severe COPD) - the MoblO2 begins to limit O2 flow at a SpO2 of 93%. The device can be manually over-ridden by the user, and should the battery run out - or the device fail for some unforeseen reason - the default position is valve open, so the users receive whatever flow of oxygen has been set on the dial. Given the substantial burdens of O2 on patients and their families, the hassles patients describe with having to monitor their SpO2 and repeatedly adjust the flow of O2 to meet their needs, patients and experts around the world have called for improvements in O2 delivery equipment. The MoblO2 is just such a remarkable improvement and a giant step forward in helping to ease the burdens of O2 on patients who require it. The purpose of this study is to investigate the effects of the MoblO2 O2 delivery device on a range of outcomes, including physical activity, amount (liters) O2 use; maintenance of adequate SpO2 levels; patient reported outcomes including symptoms, HRQL and satisfaction with the MoblO2 O2 device.
Waitlist Available
Has No Placebo
Stanford UniversityJeff Swigris, DO, MSMinnesota Health Solutions
Image of National Institutes of Health Clinical Center in Bethesda, United States.

BPL-1357 for Flu

18 - 55
All Sexes
Bethesda, MD
Background: Influenza (flu) infections are a serious global health threat. Each year, between 3 and 5 million people get the flu, and up to 500,000 die from it. Current vaccines protect against seasonal flus, but broader vaccines are needed to protect against potential flu pandemics. Objective: To test an experimental flu vaccine. Eligibility: Healthy people aged 18 to 55 years. Design: The study will last 5 to 8 months and has 2 phases, A and B. The study vaccine will be given either as a shot in the arm or as a nasal spray. Participants will receive 1 of 3 combinations: (1) study vaccine in the nose and placebo in the arm; (2) placebo in the nose and study vaccine in the arm; or (3) placebo in the nose and placebo in the arm. A placebo is just like the real vaccine but contains no active ingredients. Phase A: Participants will have 5 clinic visits over 56 days. They will receive a shot and a nasal spray at 2 of the visits, 28 days apart. At each visit, they will have a physical exam, with tests of their blood, urine, and nasal secretions. They will check their temperature at home and record any symptoms for 7 days after each vaccine. Phase B: Participants will stay in the hospital for at least 9 days. They will be infected with a flu virus. They will provide blood, urine, and nasal fluid samples. They will have tests of their heart function. They will remain in the hospital until they test negative for the flu 2 days in a row. They will have 2 follow-up visits, 4 and 8 weeks after leaving the hospital.
Phase 2
Waitlist Available
National Institutes of Health Clinical Center (+1 Sites)Luca T Giurgea, M.D.
Have you considered Ventolin Rotacaps clinical trials? We made a collection of clinical trials featuring Ventolin Rotacaps, we think they might fit your search criteria.Go to Trials
Image of Vanderbilt University Medical Center in Nashville, United States.

High vs. Standard Dose Influenza Vaccines for Flu

18+
All Sexes
Nashville, TN
This will be a follow-up study to the "Comparison of High Dose vs. Standard Dose Influenza Vaccine in Lung Allograft Recipient" study (DMID Protocol Number 22-0014) at Vanderbilt University Medical Center. Lung transplantation is a life-saving therapy for patients with advanced lung disease, and is also associated with an improvement in quality of life. However, due to the need for life-long immunosuppression to prevent acute cellular rejection and chronic lung allograft dysfunction ("chronic rejection"), lung transplant recipients are at risk for developing major infections. In fact, one-year survival is 85%, with infection being the leading cause of death within the first year post-transplant. We will conduct a follow-up phase II, randomized, double-blind trial to assess the impact of subsequent administration of two doses of HD-IIV compared to two doses of SD-IIV among lung recipients during the early post-transplant period. Demonstration of improved immunogenicity from two doses of HD-IIV over consecutive influenza seasons would provide potential broad benefit in reducing influenza disease and its associated complications in lung transplant recipients. Moreover, studying vaccine immunogenicity and safety in the same participants over consecutive years can provide insight into the influence of immunosuppression levels and allograft aging on vaccine-mediated immune modulation. This proposed study design will contribute significantly to influenza vaccination guidance and policy for the highly vulnerable lung transplant population. This proposed study is designed to address several key knowledge gaps in vaccine-mediated protection of lung transplant recipients against influenza: * Is there increased immunogenicity with administration of one or two doses of HD-IIV or SD-IIV in the subsequent season compared to two doses of HD-IIV or SD-IIV in the first season? * What is the durability of the humoral and cellular immune response between influenza seasons and does two doses of HD-IIV or SD-IIV sustain higher HAI titers compared to two doses of HD-IIV or SD-IIV in the first season? * What is the impact of maintenance immunosuppression levels on influenza vaccine immunogenicity within the same participant? * Will the optimal immunogenic vaccination strategy be associated with an acceptable long-term safety profile over successive influenza seasons, including injection-site and systemic reactions, allosensitization, and organ rejection?
Phase 2
Recruiting
Vanderbilt University Medical CenterNatahsa Halasa, MD, MPH
Image of Altasciences Inc - Kansas City in Overland Park, United States.

VNT-101 for Safety and Tolerability Study

18 - 59
All Sexes
Overland Park, KS
A randomized, double-blind, placebo-controlled Phase 1 study conducted at a single center with approximately 78 healthy adults aged 18-59 years. Part 1 Single Ascending Dose (SAD) will enroll 48 participants into six cohorts (S1-S6) to receive single oral doses of VNT-101 (100-1500 mg) or placebo under fasting or fed (S5 only) conditions. Part 2 Multiple Ascending Dose (MAD) will enroll 30 participants into three cohorts (M1-M3) to receive multiple oral doses of VNT-101 (250-750 mg BID Days 1-5, QD Day 6) or placebo under fasting conditions. Dose escalation in both parts will proceed after Protocol Safety Review Team (PSRT) review. The primary objective for Part 1 is to evaluate the safety and tolerability of single ascending oral (SAD) doses of VNT-101 in healthy adult participants under either fasting or fed conditions. The primary objective for part 2 is to evaluate the safety and tolerability of multiple ascending oral (MAD) doses of VNT-101 in healthy adult participants.
Phase 1
Recruiting
Altasciences Inc - Kansas City
Have you considered Ventolin Rotacaps clinical trials? We made a collection of clinical trials featuring Ventolin Rotacaps, we think they might fit your search criteria.Go to Trials
Image of The University of Tennessee Graduate School of Medicine in Knoxville, United States.

Nebulizer vs Inhaler for COPD

18+
All Sexes
Knoxville, TN
The purpose of this study is to compare the effectiveness of inhaled bronchodilators delivered via nebulizers vs. dry powder inhalers (DPIs) in symptomatic participants with Chronic Obstructive Pulmonary Disease (COPD) who have airflow obstruction (FEV1/FVC ≤ 70%) and show significant air trapping (RV ≥ 120% of predicted). The investigators hypothesize that, in patients with symptomatic COPD, therapy with a long-acting anti muscarinic agent/long-acting beta agonist (LAMA/LABA) combination administered by nebulizer will improve hyperinflation (increase in inspiratory capacity and reduction in residual volume) and reduce symptoms related to COPD to a greater extent than LAMA/LABA therapy given by a DPI. The study aims to demonstrate the following: 1. Compare the values of inspiratory capacity (IC) and residual volume (RV) in patients receiving LAMA/LABA by DPI with those receiving LAMA/LABA by nebulizer 2. Compare patient reported outcomes (COPD Assessment Test (CAT score), Baseline/Transition Dyspnea Index (BDI/TDI) and the St. George Respiratory Questionnaire (SGRQ) in symptomatic patients with COPD receiving LAMA/LABA by DPI with those receiving LAMA/LABA by nebulizer
Phase 4
Recruiting
The University of Tennessee Graduate School of MedicineTheravance Biopharma
Have you considered Ventolin Rotacaps clinical trials? We made a collection of clinical trials featuring Ventolin Rotacaps, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security